Technology Platform
Overview
Biothera’s technology is based on the idea of mobilizing and directing the power of the immune system against disease. Through our leadership in carbohydrate chemistry, biology and immunology, the company has developed molecules that target immune cells and can enhance the function of the immune system.
Biothera has developed a wide range of molecules that are derived from naturally occurring complex carbohydrates known as beta 1,3/1,6 glucans,. Individually, these molecules are structurally different from each other and Biothera has discovered that consequently, they selectively bind to different immune cells through different receptors. As a result, these molecules can activate different functions in those immune cells. Biothera’s technology platform has the potential for the development of drugs for a wide range of therapeutic applications.
Biothera’s primary clinical focus is oncology and the company’s lead clinical candidate is Imprime PGG® (Imprime). Biothera has completed six clinical trials with Imprime and three additional trials are ongoing. These include two Phase 2 studies for the treatment of non-small cell lung cancer and a Phase 3 clinical trial in colorectal cancer.
In addition to its clinical development program, Biothera is leveraging its scientific expertise through research collaborations with leading universities and medical institutions. Together we are expanding scientific understanding of the immune system and pioneering carbohydrate chemistry with the goal of helping patients worldwide.